Triple
T22690313
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CDK4 |
E561032
|
entity |
| Predicate | inhibitedByDrug |
P149275
|
FINISHED |
| Object | palbociclib |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: palbociclib | Statement: [CDK4, inhibitedByDrug, palbociclib]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: palbociclib Context triple: [CDK4, inhibitedByDrug, palbociclib]
-
A.
Ibrance
chosen
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
lapatinib
Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: inhibitedByDrug Context triple: [CDK4, inhibitedByDrug, palbociclib]
-
A.
usesDrug
Indicates that an entity consumes, administers, or otherwise makes use of a specified drug.
-
B.
associatedWithDrug
Indicates that an entity has a relevant relationship or connection to a specific drug, such as use, exposure, or involvement in its context.
-
C.
inhibits
Indicates that one entity prevents, restrains, or reduces the activity, effect, or occurrence of another entity.
-
D.
evaluatedDrug
Indicates that a particular drug has been assessed or tested, typically in the context of a study, experiment, or evaluation process.
-
E.
hasNotableDrug
Indicates that an entity is associated with a drug that is considered notable or significant in some recognized context.
- F. None of above. chosen
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454d71b48190a1f80af9f82b6fcf |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1789a1fd08190bce5fa0babe695d3 |
completed | April 29, 2026, 3:18 a.m. |
| PD | Predicate disambiguation | batch_69ee62b2259c819091ed1387a748b9f3 |
completed | April 26, 2026, 7:08 p.m. |
| PDg | Predicate description generation | batch_69ee8843d3308190b6e22bb98ae5c3d8 |
completed | April 26, 2026, 9:48 p.m. |
Created at: April 17, 2026, 3:13 p.m.